Epidermal growth factor receptor

Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates

Retrieved on: 
Wednesday, September 7, 2022

CAMBRIDGE, Mass., Sept. 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose escalation data from its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors during an oral plenary session at the 34th EORTC-NCI-AACR (ENA) Symposium taking place October 26-28, 2022 in Barcelona, Spain. In addition, new preclinical data will be presented in poster sessions for its ALK-selective inhibitor NVL-655 and its recently nominated HER2-selective inhibitor, NVL-330.

Key Points: 
  • In addition, new preclinical data will be presented in poster sessions for its ALK-selective inhibitor NVL-655 and its recently nominated HER2-selective inhibitor, NVL-330.
  • The ARROS-1 clinical trial is continuing to enroll patients in the Phase 1 portion of the study.
  • Clinical investigation of NVL-655 is currently ongoing in the Phase 1 portion of the ALKOVE-1 Phase 1/2 study of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors.
  • Nuvalent plans to host a conference call and webcast in conjunction with the data presentation on October 28, 2022.

Cytovation collaborates with Recurrent Respiratory Papillomatosis Foundation to expand its clinical investigations of CyPep-1 into rare neoplastic disease

Retrieved on: 
Tuesday, February 8, 2022

Recurrent Respiratory Papillomatosis (RRP) is a rare neoplastic disease that is characterized by the growth of benign tumors in the respiratory tract caused by the human papilloma virus (HPV).

Key Points: 
  • Recurrent Respiratory Papillomatosis (RRP) is a rare neoplastic disease that is characterized by the growth of benign tumors in the respiratory tract caused by the human papilloma virus (HPV).
  • The collaboration will enable Cytovation to draw upon RRPF's extensive knowledge and network in preparation for a Phase I/II study to be initiated in 2H 2022.
  • Kim McClellan, RRPF President, commented: "We are delighted to be combining our expertise with Cytovation's to help investigate CyPep-1 in RRP.
  • The Recurrent Respiratory Papillomatosis Foundation is on a mission to find a cure and ultimately eradicate RRP, so that it becomes a disease of the past.

Cytovation collaborates with Recurrent Respiratory Papillomatosis Foundation to expand its clinical investigations of CyPep-1 into rare neoplastic disease

Retrieved on: 
Tuesday, February 8, 2022

Recurrent Respiratory Papillomatosis (RRP) is a rare neoplastic disease that is characterized by the growth of benign tumors in the respiratory tract caused by the human papilloma virus (HPV).

Key Points: 
  • Recurrent Respiratory Papillomatosis (RRP) is a rare neoplastic disease that is characterized by the growth of benign tumors in the respiratory tract caused by the human papilloma virus (HPV).
  • The collaboration will enable Cytovation to draw upon RRPF's extensive knowledge and network in preparation for a Phase I/II study to be initiated in 2H 2022.
  • Kim McClellan, RRPF President, commented: "We are delighted to be combining our expertise with Cytovation's to help investigate CyPep-1 in RRP.
  • The Recurrent Respiratory Papillomatosis Foundation is on a mission to find a cure and ultimately eradicate RRP, so that it becomes a disease of the past.

Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial

Retrieved on: 
Friday, October 1, 2021

"Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR.

Key Points: 
  • "Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR.
  • The Phase I/IIa clinical trial will enroll up to 50 patients and is being conducted in Australia under contract service provided by Senz Oncology Pty Ltd.
  • The objective of this first-in-human clinical trial is to examine the safety and tolerability of EO1001 in patients with metastatic or advanced stage ErbB-1(EGFR), ErbB-2(HER2) and/or ERbB-4 (HER4) positive cancer.
  • On February 9, 2021, Edison Oncology and Apollomics announced an exclusive licensing agreement whereby Apollomics will develop and commercialize EO1001 (APL-122) globally, except in Mainland China, Hong Kong and Taiwan.

Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial

Retrieved on: 
Thursday, September 30, 2021

Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR.

Key Points: 
  • Our preclinical studies have shown that EO1001 is potent against multiple activating mutations in the intracellular domain of EGFR.
  • The Phase I/IIa clinical trial will enroll up to 50 patients and is being conducted in Australia under contract service provided by Senz Oncology Pty Ltd.
  • The objective of this first-in-human clinical trial is to examine the safety and tolerability of EO1001 in patients with metastatic or advanced stage ErbB-1(EGFR), ErbB-2(HER2) and/or ERbB-4 (HER4) positive cancer.
  • On February 9, 2021, Edison Oncology and Apollomics announced an exclusive licensing agreement whereby Apollomics will develop and commercialize EO1001 (APL-122) globally, except in Mainland China, Hong Kong and Taiwan.

Rybrevant Amivantamab FDA Approval To Drive Bispecific Antibody Sales To US 20 Billion by 2026

Retrieved on: 
Tuesday, August 3, 2021
Key Points: 
  • Recently, the progress in antibody and recombinant DNA technology, various platforms for generating bispecific antibodies has been developed.
  • In May, 2021 US FDA has granted approval to Rybrevant (Amivantamab) which is a novel bispecific antibody developed by Janssen Pharmaceuticals.
  • Rybrevant is a fully human bispecific antibody which is directed against EGFR and MET receptors.
  • Among region, US is currently dominating the global bispecific antibody market and is expected to lead the market during the forecast period.

Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors

Retrieved on: 
Friday, July 30, 2021

Preclinical data demonstrate AFM24s activation of the innate immune system, acting independently of EGFR-expression levels, EGFR-pathway mutations and downstream signal transduction.

Key Points: 
  • Preclinical data demonstrate AFM24s activation of the innate immune system, acting independently of EGFR-expression levels, EGFR-pathway mutations and downstream signal transduction.
  • The published data supported the Investigational New Drug application for the ongoing AFM24 Phase 1/2a dose escalation study.
  • The published data were the basis for the Investigational New Drug (IND) clearance for Affimeds ongoing Phase 1/2a study with AFM24 monotherapy in patients with EGFR expressing solid tumors.
  • AFM24 is effective against many EGFR-positivetumorcells, regardless of EGFR expression level and KRAS/BRAF mutational status within in vitro studies.

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Retrieved on: 
Tuesday, July 20, 2021

NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.

Key Points: 
  • NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.
  • Both product candidates are exclusively licensed forU.S.commercialization withGalderma Holding SA.
  • The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast.
  • For additional information, please visit www.sol-gel.com .

Global EGFR Tests (In Vitro Diagnostics) Market Analysis and Forecast Model 2021 with COVID-19 Market Impact - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021

The "EGFR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "EGFR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering.
  • EGFR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
  • The model discusses in detail the impact of COVID-19 on EGFR Tests market for the year 2020 and beyond.
  • The model includes EGFR Immunohistochemistry Tests, EGFR Sanger Sequencing Tests, EGFR Nucleic Acid Amplification Tests (NAATs), and EGFR Other Tests (EGFR ISH and Mass Array tests).

Preventing lung cancer's unwelcome return

Retrieved on: 
Tuesday, July 13, 2021

Cold Spring Harbor Laboratory (CSHL) Visiting Scientist Raffaella Sordella investigated a similar problem that occurs in some lung cancers .

Key Points: 
  • Cold Spring Harbor Laboratory (CSHL) Visiting Scientist Raffaella Sordella investigated a similar problem that occurs in some lung cancers .
  • Approximately 15% of non-small cell lung cancers have a mutation in a growth receptor called EGFR, causing tumor cells to grow uncontrollably.
  • Researchers developed an effective drug that inhibits EGFR and kills cancer cells, but the tumor grows back later.
  • Understanding how resistance arises in lung cancer is key to figuring out how to eliminate a tumor.